argenx SE is a prominent player in the Healthcare sector, specifically operating within the Biotechnology industry. With a substantial market capitalization of $41.09 Billion, the stock is currently trading at $663.93. Recently, the asset has experienced notable short-term weakness, declining by 3.01% over the last 24 hours and shedding 8.81% over the past seven days. This steady downward pressure has significantly compromised its immediate technical structure.

From a technical perspective, our scoring system generates a total score of -4, which strictly translates to a Strong Sell rating. The stock is deeply entrenched in a primary bearish trend, trading well below its 200-day Simple Moving Average of $749.96 (yielding -2 points). The strength of this downward trajectory is decisively confirmed by an ADX of 39.98 coupled with a DMI- (42.33) that easily overpowers the DMI+ (10.76), adding another -1 to the score. Momentum and volume indicators point toward ongoing distribution: the MACD histogram is currently negative (-5.12), and the On-Balance Volume (OBV) sits lower than its 5-day SMA (-1 point each). The only contrary signal comes from the RSI, which stands at an extremely low 22.67 (+1 point). This indicates oversold conditions, meaning a short-term technical bounce could occur, but the overarching trend remains fiercely bearish.

This bleak technical breakdown aligns almost perfectly with the company's recent fundamental and earnings data. argenx SE currently trades with a demanding P/E ratio of 33.91 and offers a 0% dividend yield, providing no fundamental cushion for value-oriented investors during drawdowns. More alarmingly, the latest earnings report revealed a deeply negative EPS of -1.87, representing a massive downside surprise of -1443.0%. With the next earnings release slated for 07/05/2026, the absence of near-term fundamental catalysts leaves the stock vulnerable. Ultimately, both the technical deterioration and the concerning fundamental backdrop fully justify the Strong Sell rating.